Profile photo Rik Verheijden

Rik Verheijden

PHD Candidate - OIO

Strategic program(s):

Recent publications

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma Mark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, Rik J Verheijden, Max F Troenokarso, Pim Moeskops, Joost J C Verhoeff, Sjoerd G Elias, Wouter A C Van Amsterdam, Femke Burgers, Franchette W P J Van Den Berkmortel, Marye J Boers-Sonderen, Martijn F Boomsma, Jan Willem De Groot, John B A G Haanen, Geke A P Hospers, Djura Piersma, Gerard Vreugdenhil, Hans M Westgeest, Ellen Kapiteijn, Mariette Labots, Wouter B Veldhuis, Paul J Van Diest, Pim A De Jong, Josien P W Pluim, Tim Leiner, Mitko Veta, Karijn P M Suijkerbuijk
Journal of the National Cancer Institute, 2025, vol. 117, p.1245-1252
Gut microbiome and immune checkpoint inhibitor toxicity Rik J Verheijden, Mick J M van Eijs, Fernanda L Paganelli, Marco C Viveen, Malbert R C Rogers, Janetta Top, Anne M May, Janneke H H M van de Wijgert, Karijn P M Suijkerbuijk,
European Journal of Cancer, 2025, vol. 216
Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story Rik J Verheijden, Jolien S de Groot, Babs O Fabriek, Miki N Hew, Anne M May, Karijn P M Suijkerbuijk
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024, vol. 43, p.616-619
Next-generation IgA-SEQ allows for high-throughput, anaerobic, and metagenomic assessment of IgA-coated bacteria Merel van Gogh, Jonas M Louwers, Anna Celli, Sanne Gräve, Marco C Viveen, Sofie Bosch, Nanne K H de Boer, Rik J Verheijden, Karijn P M Suijkerbuijk, Eelco C Brand, Janetta Top, Bas Oldenburg, Marcel R de Zoete
Microbiome, 2024, vol. 12
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy Rik J Verheijden, Jolien S de Groot, Babs O Fabriek, Miki N Hew, Anne M May, Karijn P M Suijkerbuijk
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024, vol. 42, p.3713-3724